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Abstract
Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the 
metabolic syndrome, whose criteria are risk factors for atherosclerotic cardiovascular disease. We 
aimed to evaluate the prevalence of NAFLD, its association with subclinical atherosclerosis, and 
factors that may account for this association in Mexican Americans. In a population based cross-
sectional sample drawn from the Cameron County Hispanic Cohort in Texas, carotid intima media 
thickness (cIMT), an indicator of subclinical atherosclerosis, was measured. Abnormal carotid 
ultrasound study was defined as mean cIMT >75th percentile for age and gender and/or plaque 
presence. NAFLD was defined as steatosis by ultrasound in absence of other causes of liver 
disease. Multivariable weighted regression analyses were performed to evaluate associations 
between NAFLD and cIMT. Mean age was 50.4±1.2 years with 58.3% females. Mean body mass 
index (BMI) was 31.0 ± 0.4 kg/m2, and 54.0% had the metabolic syndrome. NAFLD was highly 
prevalent (48.80%); subjects with NAFLD had greater BMI, central obesity, fasting glucose levels, 
and dyslipidemia, and were more likely to have the metabolic syndrome. Nearly one third of 
subjects with NAFLD also had evidence of subclinical atherosclerosis (31.2%). After adjusting for 
covariates, there was an independent association between NAFLD and increased cIMT only in 
younger subjects <45 years (p=0.0328). Subjects with both abnormal liver and carotid ultrasound 
studies tended to be obese, diabetic, and have the metabolic syndrome. In conclusion, NAFLD is 
highly prevalent in this Mexican American cohort, with an independent association between 
NAFLD and subclinical atherosclerosis among younger subjects; clustering of diabetes, obesity, 
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and metabolic syndrome in this health disparity cohort increases the risk of both liver disease and 
early atherosclerosis in young adults.
Keywords
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Non-alcoholic fatty liver disease (NAFLD), a comprehensive term used to describe a 
spectrum of metabolic fatty liver diseases, is the most common cause of chronic liver disease 
in the United States.1 NAFLD is considered to be the hepatic manifestation of the metabolic 
syndrome, whose criteria of central (truncal) obesity, hypertriglyceridemia, hypertension, 
decreased high-density lipoprotein cholesterol, and insulin resistance are also important risk 
factors for the development of atherosclerotic heart disease.2–3 Indeed, cardiovascular 
disease accounts for 25% of deaths in patients with NAFLD versus 13% of deaths in patients 
with other liver diseases.4 Although some investigations have shown a relationship between 
NAFLD and coronary artery disease independent of other metabolic risk factors,5 other 
studies have shown inconsistent results6–7 with relatively little known about the association 
in minority groups.8 Hispanics and Latinos face a disparately increased prevalence of 
coronary risk factors,9 and in particular, the metabolic syndrome has been shown to be 
higher in Hispanics than in non-Hispanics.10 Similarly, NAFLD afflicts Mexican Americans 
much more than non-Hispanic Whites and non-Hispanic Blacks (25% vs. 18% and 15%, 
respectively).11–12 This study aimed to evaluate the prevalence of NAFLD, its association 
with subclinical atherosclerosis, and the factors that may account for this association in 
Mexican Americans.
METHODS
The Institutional Review Board of the University of Texas Health Science Center at Houston 
approved this study with all participants giving written informed consent. Study subjects 
were drawn from the Cameron County Hispanic Cohort (CCHC), recruited from randomly 
selected blocks according to the 2000 Census as described previously.13 The CCHC is a 
homogenous community-dwelling Mexican American cohort living in Brownsville, Texas, 
located on the lower Rio Grande River at the United States-Mexico border. Participants for 
this study (n=407) were a subset of individuals drawn from the CCHC, on whom we had 
obtained both a carotid ultrasound to assess carotid intima media thickness (cIMT) and liver 
ultrasound to evaluate for fatty liver.
Bilingual research nurses and field workers obtained demographics of the participants 
including an extensive medical history as described in previous studies.13–14 Participants 
with a documented history of prior heart attack or stroke were excluded from the study. 
Anthropometric measurements were obtained including height, weight, and waist 
circumference. The presence of hypertension was diagnosed using both questionnaires and 
obtained sphygmomanometer measurements. The subject was deemed to have hypertension 
if the patient self-reported a prior diagnosis of hypertension, was currently taking anti-
hypertensive medications, or if his/her mean systolic blood pressure was ≥130 millimeters of 
mercury (mm Hg) or the mean diastolic blood pressure was ≥85 mm Hg. Participants were 
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asked to fast for at least 10 hours overnight before a visit to the Clinical Research Unit. 
Laboratory studies performed included electrolytes, fasting lipid panel, hepatitis B and C 
status, complete blood count, glycated hemoglobin, fasting plasma glucose, and adipokines. 
High-sensitivity C-reactive protein levels were measured using a high-sensitivity 
immunoassay (Dimension Vista 1500; Siemens Corporation, Washington, DC). High-
sensitivity C-reactive protein levels >10 milligrams/liter were excluded from analysis as 
such high levels likely represent acute illness.15 Metabolic syndrome was defined as the 
presence of at least 3 of the following risk factors: 1) elevated waist circumference (≥102 
centimeters in males and ≥88 centimeters in females), 2) elevated triglyceride (≥150 
milligrams/deciliter) or treatment with triglyceride lowering medication, 3) low high density 
lipoprotein cholesterol (<40 milligrams/deciliter in males and <50 milligrams/deciliter in 
females) or treatment with high-density lipoprotein cholesterol raising medication, 4) 
elevated blood pressure (systolic ≥130 mmHg and/or diastolic ≥85 mmHg) or treatment with 
an anti-hypertensive medication, and 5) elevated fasting glucose (≥100 milligrams/deciliter) 
or treatment with glucose lowering medication.16 Classification of diabetes was also both 
self-reported and based on measurement of hemoglobin A1C (hemoglobin A1C >6.5) as per 
the latest guidelines from the American Diabetes Association.17 Physical activity was 
assessed using the International Physical Activity Questionnaire short-form (IPAQ);18 
reported minutes of physical activity per week were weighted by a metabolic equivalent 
(MET; multiples of resting energy expenditure) resulting in a physical activity estimate 
expressed as MET-minutes per week.18
Any individual who tested positive for hepatitis C antibody, hepatitis B surface antigen, 
females with a self-reported history of ≥20 grams of alcohol per day, and males with a self-
reported history of ≥30 grams of alcohol per day were excluded from this study. Liver 
ultrasound was performed using an established protocol.19 Study participants were asked to 
fast for at least 8 hours prior to the ultrasound examination. During the scan, liver 
parenchyma was examined both subcostally and intercostally in the supine position as well 
as in modified slightly oblique positions with the right arm above the head and the right leg 
stretched during all respiration cycles to identify the best approach and to avoid artifacts 
caused by the thorax. For a diagnosis of hepatic steatosis, the following features were 
recorded: (1) ultrasonographic contrast between the liver and right kidney parenchyma; (2) 
brightness of the liver; (3) deep attenuation of ultrasound penetration into the deep portion of 
the liver and impaired visualization of the diaphragm; and (4) impaired visualization of the 
borders of intrahepatic vessels and narrowing of their lumen. Trained technicians perform 
ultrasonography with a 5 mega-Hertz transducer (Ch5-2, Siemens, Mountain View, CA). 
The overall gain, initial gain, and time gain compensation settings were kept within a narrow 
range. The ultrasonographic images were read and interpreted by a single blinded expert 
reader.
Carotid ultrasound to evaluate subclinical atherosclerosis was performed with the Siemens 
Acuson X300 ultrasound system (Malvern, PA) using a VF 13-5 linear array transducer as 
described in previous studies.14 The protocol was designed following guidelines from the 
American Society of Echocardiography consensus statement on subclinical vascular disease.
20 Both left and right common carotid arteries were imaged from 3 different angles for a 
total of 6 images: anterior, lateral, and posterior images for both common carotid arteries. 
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Carotid plaque presence was determined by examining the carotid bulb, its bifurcation and 
the carotid branch arteries in addition to the common carotid artery. Carotid IMT was 
measured using the Carotid Analyzer software (Medical Imaging Applications, Coralville, 
IA), a semi-automated border detection program. Measurements were made at the R-wave of 
the electrocardiogram on a minimum of 2 clips from each side and the results were 
averaged. Mean cIMT was categorized as being either < or ≥75th percentile for age and 
gender.20 Carotid plaque was defined as an area of wall thickening that was >50% of the 
thickness of the surrounding wall. A single blinded expert reader similarly performed all 
measurements. Replicate readings were performed on 5% of the cohort and the intra-class 
correlation coefficient for our laboratory was 0.96. Abnormal carotid ultrasound study was 
defined as mean cIMT thickness ≥75th percentile for age and gender and/or the presence of 
carotid plaque.
All descriptive results and the models reported were adjusted for the probability of sampling 
using age and gender adjusted sampling weights and taking into consideration clustering 
effects arising from multiple participants from the same household as well as census tracks 
and blocks.13 Descriptive statistics of baseline demographics and clinical characteristics 
were reported and compared by NAFLD/Abnormal Carotid Ultrasound groups. Data were 
summarized as mean and standard error for continuous variables and frequency and 
weighted column percentages for categorical variables. Continuous variables were compared 
using survey-weighted linear regression models from which Tukey-Kramer-adjusted p 
values were calculated. Survey-weighted logistic regression was used to compare categorical 
variables and to obtain the Rao-Scott F-adjusted chi-square p values. Survey-weighted 
multivariable linear regression model was constructed to evaluate the effect of abnormal 
fatty liver ultrasound on cIMT adjusting for demographic and clinical variables found to be 
significantly associated with cIMT with p-value<0.05. To determine factors associated with 
both abnormal liver and abnormal carotid, we conducted survey-weighted multinomial 
multivariable logistic regression. Potential multi-collinearity and interaction effects across 
the predictors in the multivariable models were assessed. All analyses were performed using 
SAS 9.3 (SAS, 2000). Statistical significance was set at p < 0.05.
RESULTS
Demographic and biochemical characteristics are listed in Table 1. This study included 407 
individuals with an average age of 50.4 ± 1.2 years and females making up 58.3% of the 
sample. There was a high prevalence of coronary risk factors in this cohort. The majority of 
the individuals were either overweight or obese (85.6%), and only 14.4% had a normal body 
mass index (BMI) [mean BMI of 31.0 ± 0.4 kg/m2].
NAFLD was demonstrated in nearly half (49.2%) of the study participants with no gender 
difference in prevalence (42.2% in males and 57.8% in females, p=0.8800). Compared to 
subjects without NAFLD, subjects with NAFLD had higher BMI (32.5±0.5 kg/m2 versus 
29.5±0.7 kg/m2; p=0.0005), larger waist circumference (106.5±1.2 centimeter. versus 
100.2±1.6 centimeter; p=0.0024), had higher fasting blood glucose (114.9±5.3 milligram/
deciliter versus 99.8±1.6 milligram/deciliter; p=0.0058) and hemoglobin A1C (6.4%±0.2 
versus 5.8%±0.1; p=0.0006), had higher fasting triglycerides (168.6±7.6 milligram/deciliter 
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versus 127.0±6.4 milligram/deciliter; p<0.0001), had higher Homeostasis Model 
Assessment Insulin Resistance Index (4.7±0.6 versus 3.1±0.3, p=0.0225), had lower high 
density lipoprotein cholesterol levels (43.0±1.1 milligram/deciliter versus 47.8±1.6 
milligram/deciliter; p=0.0107), and lower adiponectin levels (14.6±1.3 micrograms versus 
20.8±1.4 micrograms; p=0.0017). Patients with NAFLD had higher prevalence of metabolic 
syndrome compared to those without (70.1% versus 38.5%; p<0.0001). Age, gender, family 
history, blood pressure, low-density lipoprotein cholesterol, level of physical activity, high-
sensitivity C-reactive protein, and other inflammatory markers did not differ significantly 
between the two groups.
The mean cIMT for the cohort was 0.7 ± 0.0 millimeter, with no gender differences 
(p=0.4966). There was no difference in mean cIMT between those with NAFLD vs. those 
without NAFLD (p=0.2679). More than one third of the cohort (35.1%) had abnormal 
carotid ultrasound findings. Among those with NAFLD, 30.4% had evidence of subclinical 
atherosclerosis. When participants were categorized into four groups based on normal or 
abnormal carotid and liver ultrasound studies (Table 1 and Figure 1), there was a graded 
increase in prevalence for metabolic syndrome (p<0.0001), obesity (p<0.0001), and diabetes 
mellitus (p<0.0001) among groups.
Using a multivariable survey weighted logistic regression model, the odds of the presence of 
both abnormal carotid and liver ultrasound vs. normal carotid and liver ultrasound increased 
by 5% with each 1 milligram/deciliter increase in fasting plasma glucose (odds ratio=1.05, 
95% confidence interval 1.02–1.08), after controlling for age, gender, family history, BMI, 
systolic blood pressure, fasting triglycerides, physical activity, and smoking status. In further 
analysis, after controlling for covariates, using multivariable survey weighted linear 
regression models in age domains, NAFLD was independently associated with mean cIMT 
in younger individuals of ages < 45 years (p=0.0309), but not in older individuals of ages ≥ 
45 years (p=0.1891).
DISCUSSION
This study shows for the first time that in young Mexican Americans (< 45 years of age), the 
presence of NAFLD portends an increased risk of subclinical atherosclerosis independent of 
traditional coronary risk factors. Although the independent association between NAFLD and 
subclinical atherosclerosis has been demonstrated in young individuals by other 
investigators,21–22 these studies involved non-Hispanic Whites and Blacks. To our 
knowledge, this study is the first demonstration of this phenomenon in Hispanics. With a 
national prevalence of approximately 20%, NAFLD is becoming a public health concern 
with rising diabetes and obesity rates yearly especially in younger individuals. Indeed, in our 
cohort, NAFLD was seen in nearly half of the sample (49.2%), which is more than twice the 
prevalence reported nationally. Our study highlights the importance of screening for 
subclinical atherosclerosis in individuals with NAFLD especially in those persons < 45 years 
of age. The presence of NAFLD should alert the clinician to screen for early atherosclerosis, 
with the goal of intensification of risk factor modification to reduce the risk of a first 
cardiovascular disease event.
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We, along with others, have demonstrated very high prevalence of cardiovascular risk factors 
among Hispanics,9,14,23 with Mexican Americans showing epidemic proportions for obesity, 
diabetes, and the metabolic syndrome.14 The high prevalence of NAFLD in this minority 
group is therefore not surprising, and our present study is consistent with previous reports 
that showed that individuals with NAFLD were more likely to be obese, diabetic, 
dyslipidemic, and have increased visceral adiposity. In this study, we also demonstrated that, 
among Mexican Americans, adiponectin levels were lower in those with NAFLD compared 
to those without NAFLD. This finding has also been found amongst Asians and non-
Hispanic Whites24–25 but to our knowledge is the first time to be reported among Mexican 
Americans. Hypoadiponectinemia is hypothesized to be part of a general metabolic 
disturbance characterized by ectopic fat accumulation in the central compartment and 
dysfunctional adipose tissue.25 Our finding of reduced adiponectin levels in Mexican 
Americans with NAFLD is consistent with these findings and supports the role of 
adipocytokines in metabolism and glucose tolerance.
Impaired fasting glucose is a major component of the metabolic syndrome. In this study, 
among the cardiometabolic risk factors evaluated, only fasting plasma glucose remained an 
independent risk factor for both NAFLD and subclinical atherosclerosis, after adjusting for 
covariates in this cohort. For every 1 milligram/deciliter increase in fasting plasma glucose, 
there was an increase in the odds of having both NAFLD and subclinical atherosclerosis by 
5%. This is another novel finding, and is particularly relevant among Hispanics who have a 
very high prevalence of diabetes and prediabetes. In this study, the association between 
fasting plasma glucose and both NAFLD and subclinical atherosclerosis was independent of 
BMI, waist circumference, or physical activity, suggesting that these factors do not modify 
the risk for having both conditions. On the other hand, fasting plasma glucose appears to be 
an important determinant for increased risk of both hepatic and vascular end organ damage 
in this cohort. This is an intriguing finding, as it seems to emphasize the importance of 
glucose control among diabetics and plasma glucose level maintenance in those who are not, 
thereby posing potential therapeutic targets for prevention of these diseases in Mexican 
Americans.
A few limitations must be noted. This was a cross-sectional study and as such no causal 
relationships can be made, however longitudinal follow-up studies are currently underway. 
Although liver biopsy and magnetic resonance spectroscopy are considered the gold 
standards for the diagnosis of NAFLD,26 these are invasive and/or expensive tests, which are 
not feasible in this community dwelling cohort. Since individuals found to have NAFLD by 
ultrasonography had to be at least in the moderate stage of the disease and this technique can 
miss mild cases, the findings in this study represent probably more advanced disease states 
thus increasing specificity of the diagnosis. In this study, we did not perform imaging studies 
to quantitate visceral adiposity and more sensitive measures of central adiposity may yield 
different results; these studies are underway.
Acknowledgments
This work was supported by MD000170 P20 funded from the National Center on Minority Health and Health 
Disparities, and the Centers for Translational Science Award 1U54RR023417-01 from the National Center for 
Research Resources.
Gill et al. Page 6













We would like to acknowledge Dr. Belinda Reininger for her help with the physical activity data. We thank our 
cohort team, particularly, Rocio Uribe, Emma Molina, Jody Rodriguez, and their team, who not only recruited and 
documented the participants, but also performed the ultrasound studies under expert supervision. We also thank 
Marcela Montemayor and Israel Hernandez and their teams for laboratory and data support, and Norma Perez-
Olazaran and Christina Villarreal for administrative support. We thank Valley Baptist Medical Center, Brownsville, 
Texas for providing us space for our Center for Clinical and Translational Science Clinical Research Unit. We also 
thank the community of Brownsville and the participants who so willingly participated in this study in their city.
References
1. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for 
non-alcoholic fatty liver disease. Arq Gastroenterol. 2012; 49:89–96. [PubMed: 22481692] 
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, 
Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. 
Diabetes. 2001; 50:1844–1850. [PubMed: 11473047] 
3. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular 
disease: the plot thickens. Diabet Med. 2007; 24:1–6.
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural 
history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 
129:113–121. [PubMed: 16012941] 
5. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. 
Atherosclerosis. 2007; 191:235–240. [PubMed: 16970951] 
6. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-
media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204:521–
525. [PubMed: 18947828] 
7. Nahandi MZ, Khoshbaten M, Ramazanzadeh E, Abbaszadeh L, Javadrashid R, Shirazi KM, 
Gholami N. Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a 
risk factor for atherosclerosis. Gastroenterol Hepatol Bed Bench. 2014; 7:55–62. [PubMed: 
25436098] 
8. Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. Nonalcoholic fatty liver disease and carotid 
artery atherosclerosis in children and adults: a meta-analysis. Eur J Gastroenterol Hepatol. 2015; 
27:1237–1248. [PubMed: 26193052] 
9. Daviglus ML, Talavera GA, Avilés-Santa M, Allison M, Cai J, Criqui MH, Gellman M, Giachello 
AL, Gouskova N, Kaplan RC, LaVange L, Penedo F, Perreira K, Pirzada A, Schneiderman N, 
Wassertheil-Smoller S, Sorlie PD, Stamler J. Prevalence of major cardiovascular risk factors and 
cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United 
States. JAMA. 2012; 308:1775–1784. [PubMed: 23117778] 
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings 
from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287:356–359. 
[PubMed: 11790215] 
11. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, 
Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the third National 
Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013; 178:38–45. 
[PubMed: 23703888] 
12. Schneider ALC, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease 
in the U.S. population. Obesity. 2014; 22:292–299. [PubMed: 23512725] 
13. Fisher-Hoch SP, Rentfro AR, Salinas JJ, Perez A, Brown HS, Reininger BM, Restrepo BI, Wilson 
JG, Hossain MM, Rahbar MH, Hanis CM, McCormick JB. Socioeconomic status and prevalence 
of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004–2007. 
Prev Chronic Dis. 2010; 7:A53. [PubMed: 20394692] 
14. Laing ST, Smulevitz B, Vatcheva KP, Rahbar MH, Reininger B, McPherson DD, McCormick JB, 
Fisher-Hoch SP. Subclinical atherosclerosis and obesity phenotypes among Mexican Americans. J 
Am Heart Assoc. 2015; 4:e001540. [PubMed: 25787312] 
15. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann 
SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease 
Gill et al. Page 7













Control and Prevention: American Heart Association. Markers of inflammation and cardiovascular 
disease: application to clinical and public health practice: a statement for healthcare professionals 
from the Centers for Disease Control and Prevention and the American Heart Association. 
Circulation. 2003; 107:499–511. [PubMed: 12551878] 
16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, 
Loria CM, Smith SC, International Diabetes Federation Task Force on Epidemiology and 
Prevention; National Heart, Lung Blood Institute; American Heart Association, World Heart 
Federation; International Atherosclerosis Society; International Association for the Study of 
Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International 
Diabetes Federation Task Force, the National Heart Lung and Blood Institute, the American Heart 
Association (AHA), the World Heart Federation, the International Atherosclerosis Society, and the 
International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645. [PubMed: 
19805654] 
17. International Expert Committee. International Expert Committee Report on the role of the A1C 
assay in the diagnosis of diabetes. Diabetes Care. 2009; 32:1327–1334. [PubMed: 19502545] 
18. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, 
Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and 
validity. Med Sci Sports Exerc. 2003; 35:1381–1395. [PubMed: 12900694] 
19. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida 
K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in 
nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am 
J Gastroenterol. 2007; 102:2708–2715. [PubMed: 17894848] 
20. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post 
WS, American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of 
carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: 
a consensus statement from the American Society of Echocardiography Carotid Intima-Media 
Thickness Task Force endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 
2008; 21:93–111. [PubMed: 18261694] 
21. VanWagner LB, Ning H, Lewis CE, Shay CM, Wilkins J, Carr JJ, Terry JG, Lloyd-Jones DM, 
Jacobs DR Jr, Carnethon MR. Associations between nonalcoholic fatty liver disease and 
subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young 
Adults Study. Atherosclerosis. 2014; 235:599–605. [PubMed: 24956534] 
22. Koskinen J, Magnussen CG, Kähönen M, Loo BM, Marniemi J, Jula A, Saarikoski LA, 
Huupponen R, Viikari JS, Raitakari OT, Juonala M. Association of liver enzymes with metabolic 
syndrome and carotid atherosclerosis in young adults. The Cardiovascular Risk in Young Finns 
Study. Ann Med. 2012; 44:187–195. [PubMed: 21254896] 
23. Rodriguez CJ, Allison M, Daviglus ML, Isasi CR, Keller C, Leira EC, Palaniappan L, Pina IL, 
Ramirez SM, Rodriguez B, Sims M, American Heart Association Council on Epidemiology and 
Prevention; American Heart Association Council on Clinical Cardiology; American Heart 
Association Council on Cardiovascular and Stroke Nursing. Status of cardiovascular disease and 
stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart 
Association. Circulation. 2014; 130:593–625. [PubMed: 25098323] 
24. Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent association between nonalcoholic fatty liver 
disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol. 2013; 
2013:124958. [PubMed: 23690766] 
25. Misra VL, Khashab M, Chalasani N. Non-alcoholic fatty liver disease and cardiovascular risk. Curr 
Gastroenterol Rep. 2009; 11:50–55. [PubMed: 19166659] 
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, 
Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis 
Clinical Research Network. Design and validation of a histological scoring system for 
nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313–1321. [PubMed: 15915461] 
Gill et al. Page 8














Weighted Prevalence of Metabolic Syndrome, Obesity and Diabetes among Mexican 
Americans within Non-Alcoholic Fatty Liver Disease/Subclinical Atherosclerosis Groups. 
(NAFLD = Non-Alcoholic Fatty Liver Disease)
Gill et al. Page 9






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Am J Cardiol. Author manuscript; available in PMC 2018 September 11.
